Tunable vaccine platform against pathogens of the paramyxovirus family
AssigneeGeorgia State University Research Foundation, Inc.
InventorsRichard Plemper, Veronika von Messling
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a strategy for the engineering of recombinant vaccines against major human and animal pathogens of the paramyxovirus family. Also disclosed are recombinant virus able to replicate without being pathogenic. Also disclosed is a method of immunizing a subject against infection with a that involves administering to the subject a recombinant vaccine disclosed herein.
Claims16
A recombinant non-pathogenic paramyxovirus vaccine, comprising a paramyxovirus genome encoding an infectious paramyxovirus virion operably linked to an expression control sequence, wherein the paramyxovirus genome comprises a nucleic acid encoding a nucleoprotein having a deletion that allows a paramyxovirus virus produced by expression of the paramyxovirus vector to replicate without being pathogenic, wherein the deletion corresponds to residues 442-480 of SEQ ID NO:1.
A recombinant nucleic acid, comprising a paramyxovirus nucleoprotein having a deletion that allows a paramyxovirus virus produced by expression of the paramyxovirus vector to replicate without being pathogenic, operably linked to a heterologous expression control sequence, wherein the deletion corresponds to residues 442-480 of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.